Tau Kinetics in Neurons and the Human Central Nervous System

Sato, Chihiro, Barthélemy, Nicolas R., Mawuenyega, Kwasi G., Patterson, Bruce W., Gordon, Brian A., Jockel-Balsarotti, Jennifer, Sullivan, Melissa, Crisp, Matthew J. +9 more·2018·Neuron
DOI 10.1016/j.neuron.2018.02.015

Cited by (584)

Items 401–500 of 584

  1. Defining patient‐centered amyloid PET thresholds for the onset of tauopathy in Alzheimer's disease
    Zeyu Zhu, Anna Steward, Amir Dehsarvi, Sebastian Niclas Roemer, Anna Dewenter, Davina Biel, Fabian Hirsch, Lukas K. Frontzkowski, Julia Pescoller, Madleen Klonowski et al. · 2026 · Alzheimer s & Dementia
  2. Protein tau concentration in blood increases after SCUBA diving: an observational study
    Anders Rosén, Mikael Gennser, Nicklas Oscarsson, Andreas Kvarnström, Göran Sandström, Helen Seeman-Lodding, Joel Simrén, Henrik Zetterberg · 2022 · European Journal of Applied Physiology
  3. CSF p-tau231: A biomarker for early preclinical Alzheimer?
    Marc Suárez‐Calvet · 2022 · EBioMedicine
  4. Differentiation of Human Induced Pluripotent Stem Cells into Cortical Neurons to Advance Precision Medicine
    M. Catarina Silva, Ghata Nandi, Stephen J. Haggarty · 2022 · Methods in molecular biology
  5. Long-Term Depression-Inducing Low Frequency Stimulation Enhances p-Tau181 and p-Tau217 in an Age-Dependent Manner in Live Rats
    Yangyang Zhang, Yin Yang, Zhengtao Hu, Manyi Zhu, Shuangying Qin, Pengpeng Yu, Bo Li, Ji‐Tian Xu, Tomáš Ondrejčák, Igor V. Klyubin et al. · 2022 · Journal of Alzheimer s Disease
  6. Blood MAPT expression and methylation status in Alzheimer's disease
    Hiroaki Mori, Yuta Yoshino, Mariko Ueno, Yu Funahashi, Hiroshi Kumon, Yuki Ozaki, Kiyohiro Yamazaki, Shinichiro Ochi, Jun‐ichi Iga, Shuichi Ueno · 2022 · Psychiatry and Clinical Neurosciences Reports
  7. Rosuvastatin attenuates total-tau serum levels and increases expression of miR-124-3p in dyslipidemic Alzheimer's patients: a historic cohort study
    Farnoosh Usefi, Auob Rustamzadeh, Zahra Ghobadi, Nader Sadigh, Nafiseh Mohebi, Armin Ariaei, Fatemeh Moradi · 2024 · Metabolic Brain Disease
  8. Untangling the tau microtubule-binding region
    Jamie Toombs, Henrik Zetterberg · 2020 · Brain
  9. Identification of Sulfonamide-Based Butyrylcholinesterase Inhibitors Using Machine Learning
    Ankit Ganeshpurkar, Ravi Singh, Devendra Kumar, Gopichand Gutti, Pravin Gore, Bharat Lal Sahu, Ashok Kumar, Sushil Kumar Singh · 2022 · Future Medicinal Chemistry
  10. CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
    Ruocheng Dong, Burcu F. Darst, Yuetiva K. Deming, Yue Ma, Qiongshi Lu, Henrik Zetterberg, Kaj Blennow, Cynthia M. Carlsson, Sterling C. Johnson, Sanjay Asthana et al. · 2021 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  11. Changes of the Primary Cilia in Alzheimer's Disease Pathogenesis
    Guo, Angyang, Wang, Han, Zhang, Yan, Huang, Hongbin · 2025 · European Journal of Neuroscience
  12. MAPT-A152T mutation drives neuronal hyperactivity through Fyn-NMDAR signaling in human iPSC-Derived neurons: Insights into Alzheimer's pathogenesis
    Maika Itsuno, Hirokazu Tanabe, Etsuko Sano, Takashi Sasaki, Chisato Oyama, Hiroko Bannai, Koichi Saito, Kazuhiko Nakata, Setsu Endoh‐Yamagami, Hideyuki Okano et al. · 2024 · Regenerative Therapy
  13. A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease
    Davina Biel, Anna Steward, Anna Dewenter, Amir Dehsarvi, Zeyu Zhu, Sebastian Niclas Roemer, Lukas K. Frontzkowski, Fabian Hirsch, Carla Palleis, Günter U. Höglinger et al. · 2025 · Alzheimer s & Dementia
  14. Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System
    Rama K. Koppisetti, Nicolas R. Barthélemy, Kanta Horie, Cindy V. Ly, Kaleigh F. Roberts, Srinivas Koutarapu, Richard J. Perrin, Erin E. Franklin, Chiara Pedicone, Joshua Orrick et al. · 2026 · Annals of Neurology
  15. Proteomic Markers and Early Prediction of Alzheimer’s Disease
    Natalia V. Zakharova, Anna E. Bugrova, Maria I. Indeykina, Ya. B. Fedorova, Игорь Владимирович Колыхалов, Gavrilova Si, Е. Н. Николаев, Alexey S. Kononikhin · 2022 · Biochemistry (Moscow)
  16. Label-Free Multimetric Measurement of Molecular Binding Kinetics by Electrical Modulation of a Flexible Nanobiolayer
    Xiaoyan Zhou, Guangzhong Ma, Zijian Wan, Shaopeng Wang · 2022 · ACS Sensors
  17. Rapidly reversible persistent long-term potentiation inhibition by patient-derived brain tau and amyloid ß proteins
    T. Ondrejčák, I. Klyubin, Neng-Wei Hu, Yin Yang, Qian-Cheng Zhang, Brian J. Rodriguez, Michael J. Rowan · 2024 · Philosophical Transactions B
  18. Single-Cell RNA Sequencing Reveals Immunomodulatory Effects of Stem Cell Factor and Granulocyte Colony-Stimulating Factor Treatment in the Brains of Aged APP/PS1 Mice
    Robert S. Gardner, Michele M. Kyle, Karen Hughes, Li‐Ru Zhao · 2024 · Biomolecules
  19. Neuroprotective role of Fisetin in Alzheimer's disease: An overview of potential mechanism and clinical findings
    Fardin Nabizadeh · 2024 · Neurology Letters
  20. Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy
    Takanobu Ishiguro, Kensaku Kasuga · 2024 · Brain Sciences
  21. Patient-derived tau and amyloid-β facilitate long-term depression in vivo: role of tumour necrosis factor-α and the integrated stress response
    Neng‐Wei Hu, Tomáš Ondrejčák, Igor V. Klyubin, Yin Yang, Dominic M. Walsh, Frederick J. Livesey, Michael J. Rowan · 2024 · Brain Communications
  22. Alzheimers's disease: Epidemiological characteristics and its prevention
    Jovan Grujičić, Aleksandra Nikolić · 2021 · Zdravstvena zastita
  23. Using stable isotope labeling to advance our understanding of Alzheimer’s disease etiology and pathology
    Timothy J. Hark, Jeffrey N. Savas · 2021 · Journal of Neurochemistry
  24. A novel high-throughput screening strategy for targeting alpha-synuclein and other long-lived proteins
    Evan K. Casalino, Laurel B. Stine, Aaron J. Corin, Chuong-Thu Thai, Jose Quiroz, Stephen C. Wilson, Mark Labow, Shuchi Mittal · 2022 · SLAS DISCOVERY
  25. The image quality, amyloid-β detectability, and acquisition time of clinical florbetapir positron emission tomography in Alzheimer’s disease and healthy adults
    Hongsheng Xie, Yuhao Li, Xiaoai Wu, Ruihan Wang, Xipeng Long, Minggang Su, Qin Chen, Lin Li, Rong Tian, Zhiyun Jia · 2023 · Quantitative Imaging in Medicine and Surgery
  26. Preoperative Plasma p-tau231, p-tau181, and p-tau217 Are Associated With Postoperative Delirium: A Prospective Study
    LiXue Wu, JiaBao Su, Guangping Li, Meng Zhuang, HaiJian Sun, Jiru Zhang · 2025 · The Journals of Gerontology Series A
  27. ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
    Anna Steward, Anna Dewenter, Fabian Hirsch, Sebastian Niclas Roemer, Zeyu Zhu, Amir Dehsarvi, Davina Biel, Madleen Klonowski, Lukas K. Frontzkowski, Carla Palleis et al. · 2025 · Brain
  28. Sequestosome-1 (SQSTM1/p62) as a target in dopamine catabolite-mediated cellular dyshomeostasis
    Anna Masato, Annapaola Andolfo, Giulia Favetta, Edoardo Niccolò Bellini, Susanna Cogo, Luisa Dalla Valle, Daniela Boassa, Elisa Greggio, Nicoletta Plotegher, Luigi Bubacco · 2024 · Cell Death and Disease
  29. Aqueous extractable nonfibrillar and sarkosyl extractable fibrillar Alzheimer’s disease tau seeds have distinct properties
    Anastasie Maté de Gérando, Anita Khasnavis, Lindsay A. Welikovitch, Harshil Bhavsar, Calina A. Glynn, Noé Quittot, Romain Perbet, Bradley T. Hyman · 2024 · Acta Neuropathologica Communications
  30. The Current Role of Tau PET Imaging in Neurodegeneration
    Greet Vanderlinden, Rik R. Vandenberghe, Mathieu Vandenbulcke, Koen Van Laere · 2025 · Seminars in Nuclear Medicine
  31. Generation of human induced pluripotent stem cell-derived cortical neurons expressing the six tau isoforms
    Jiang, Houbo, Xiao, Zichun, Saleem, Komal, Zhong, Ping, Li, Li, Chhetri, Gaurav, Li, Pei, Jiang, Zhongjiao, Yan, Zhen, Feng, Jian · 2025 · Journal of Alzheimer’s Disease
  32. Biomarkers of neuronal damage in saturation diving—a controlled observational study
    Anders Rosén, Mikael Gennser, Nicklas Oscarsson, Andreas Kvarnström, Göran Sandström, Kaj Blennow, Helen Seeman-Lodding, Henrik Zetterberg · 2020 · European Journal of Applied Physiology
  33. Extracellular vesicles in Alzheimer's disease
    Victor Hugo Berriel Pinho, João Paulo Lima Daher, Salim Kanaan, Thalia Medeiros · 2024 · Arquivos de Neuro-Psiquiatria
  34. Emerging drugs for progressive supranuclear palsy
    Nikolaos Giagkou, María Stamelou · 2019 · Expert Opinion on Emerging Drugs
  35. Benefit and safety of antibiotics for Alzheimer’s disease: Protocol for a systematic review and meta-analysis
    Lin Gao, Yinqi Shuai, Lihong Wen, Hong Zhang, Yi Zhang, Xiaoyun Zhang · 2022 · Medicine
  36. IP-LC-MSMS Enables Identification of Three Tau O-GlcNAcylation Sites as O-GlcNAcase Inhibition Pharmacodynamic Readout in Transgenic Mice Overexpressing Human Tau
    Sebastiaan Bijttebier, Dina Rodrigues Martins, Liesbeth Mertens, Karolien Grauwen, Wouter Bruinzeel, Roland Willems, José Manuel Bartolomé-Nebreda, Clara Theunis, Alexis Bretteville, Andreas Ebneth et al. · 2023 · Journal of Proteome Research
  37. Tracking the turning point in Alzheimer’s disease
    Bart De Strooper, Henrik Zetterberg · 2026 · Science
  38. Radiomics of PET Using Neural Networks for Prediction of Alzheimer's Disease Diagnosis
    Yimo Zhang, Jon Arni Steingrimsson, Akhil Ambekar, Hwamee Oh, Ani Eloyan, Alzheimer’s Disease Neuroimaging Initiative · 2025 · Statistics in Medicine
  39. Relationships of PGRN with sTREM2 in AD continuum and non-AD pathophysiology and their reciprocal roles in modulating amyloid pathology: two population-based study
    Liangyu Huang, Chen‐Chen Tan, Wei Xu, Lan Tan, Alzheimer’s Disease Neuroimaging Initiative, Michael Walter Weiner, Paul S. S Aisen, Ronald Carl Petersen, Clifford R. Jack, William Jagust et al. · 2025 · Translational Psychiatry
  40. A novel lncRNA FAM151B-DT regulates degradation of aggregation prone proteins
    Arun Renganathan, Miguel Minaya, Matthew Broder, Isabel Alfradique‐Dunham, Rebecca L. Miller, Dhruva D. Dhavale, Michelle Moritz, Reshma Bhagat, Jacob A. Marsh, Anthony C. Verbeck et al. · 2025 · Molecular Psychiatry
  41. HMGB1 Box A gene therapy reverses cognitive and neuropathological features in AlCl₃/D-galactose rat model of Alzheimer's disease
    Suangsuda Supasai, Pakawat Suntaratti, Mingkwan Odton, Tasneem Longji, Thararat Karananan, Sakawdaurn Yasom, Sumate Ampawong, Yanin Limpanont, Apiwat Mutirangura · 2025 · Experimental Neurology
  42. Advances in Alzheimer’s disease: mechanistic insights and therapeutic targets
    Yu-Juan Jia, Yi‐Jun Ge, Bowei Li, Ying Yang, Huaqiu Chen, Jie Liu, Junhong Guo, Jin‐Tai Yu, Keqiang Ye, Jian‐Zhi Wang et al. · 2026 · Science China Life Sciences
  43. Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis
    Stephan A. Kaeser, Stephanie A. Schultz, Anna Hofmann, Lisa M. Häsler, Ying Xu, Marius Lambert, Ulrike Obermüller, Kathrin Brockmann, Johan Bijzet, Hans L. A. Nienhuis et al. · 2026 · Nature Medicine
  44. Making tau amyloid models in vitro: a crucial and underestimated challenge
    Julien Broc, Clara Piersson, Yann Fichou · 2025 · FEBS Letters
  45. The MIR-NAT MAPT-AS1 does not regulate Tau expression in human neurons
    Rafaela Policarpo, Leen Wolfs, Saúl Martínez‐Montero, Lina Vandermeulen, Ines E. Royaux, Gert Van Peer, Pieter Mestdagh, Annerieke S. R. Sierksma, Bart De Strooper, Constantin van Outryve d’Ydewalle · 2025 · PLoS ONE
  46. Unravelling Alzheimer's Disease: It's Not the Whole Story, but Aβ Still Matters
    Joel N. Buxbaum · 2019 · The FASEB Journal
  47. Association between serum urate and CSF markers of Alzheimer's disease pathology in a population‐based sample of 70‐year‐olds
    Tahzeeb Fatima, L. Jacobsson, Silke Kern, Anna Zettergren, Kaj Blennow, Henrik Zetterberg, Lena Havstam Johansson, Mats Dehlin, Ingmar Gr. Skoog · 2021 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  48. Hybrid LC–MS as A Powerful Tool for Supporting Protein Bioanalysis in Gene and Cell Therapies
    Wei Dong, Youngjae Kim, Hiroshi Sugimoto, Linlin Dong, Mark G. Qian · 2020 · Bioanalysis
  49. Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease
    Abdolhossein Zare, Saeede Salehi, Jakob Maximilian Bader, Anna-Lena Wiessler, Manuela Prokesch, Vincent Albrecht, Carmen Villmann, Matthias Mann, Michael Briese, Michael Sendtner · 2025 · Translational Neurodegeneration
  50. Exercise upregulates Mitsugumin 53 and ameliorates behavioral deficits and mitochondrial biogenesis in a sporadic Alzheimer's disease model in rats
    Muaz Belviranlı, Nilsel Okudan, Tuğba Sezer · 2025 · Archives of Gerontology and Geriatrics
  51. Characterizing the onset and progression of Alzheimer’s pathologies using amyloid and tau PET imaging and plasma p-tau217
    Karly Alex Cody, Rebecca E Langhough, Shorena Janelidze, Erin McMullen Jonaitis, Rachael E. Wilson, Bradley T. Christian, Sanjay Asthana, Sterling C. Johnson, Henrik Zetterberg, Oskar Hansson et al. · 2025 · Brain Communications
  52. Targeted tau protein degradation: a promising therapeutic approach for tauopathies
    Narjes Baazaoui, Mohammad Yahya Alfaifi, Ali Abdullah Shati, Rania Ben Saad, Stefanıa Garzoli · 2025 · Neuroscience
  53. Plasma NT1 tau is associated with hypometabolism in Alzheimer’s disease continuum
    Zahra Ghahri Lalaklou, AmirHossein Montazeri Ghahjavarestani, Yasamin Pishkari, Delaram Emami · 2024 · Neurology Letters
  54. Inhibition of amyloid beta oligomer accumulation by NU-9: A unifying mechanism for the treatment of neurodegenerative diseases
    Elizabeth Anne Johnson, Raghad Nowar, Kirsten L. Viola, Weijian Huang, Sihang Zhou, Maira Assunção Bicca, Wei Zhu, Daniel L. Kranz, William L. Klein, Richard B. Silverman · 2025 · Proceedings of the National Academy of Sciences
  55. Stability and Inter-domain Interactions Modulate Amyloid Binding Activity of a General Amyloid Interaction Motif
    Eva Asp, Ming Proschitsky, Michal Lulu, Cassandra Rockwell‐Postel, Haim Tsubery, Rajaraman Krishnan · 2019 · Journal of Molecular Biology
  56. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium
    Nathalie Bodd Halaas, Henrik Zetterberg, Ane‐Victoria Idland, Anne‐Brita Knapskog, Leiv Otto Watne, Kaj Blennow · 2021 · Journal of Alzheimer s Disease
  57. Evolution of Detecting Early Onset of Alzheimer’s Disease: From Neuroimaging to Optical Immunoassays
    Wesley Wei‐Wen Hsiao, Stefanny Angela, Trong‐Nghia Le, Chia‐Chi Ku, Po‐Sheng Hu, Wei‐Hung Chiang · 2023 · Journal of Alzheimer s Disease
  58. An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS
    Wade K. Self, Khader Awwad, John P. Savaryn, Michael Schulz · 2022 · PLoS ONE
  59. Soluble form of the APP fragment, sAPPβ, positively regulates tau secretion
    Haruaki Sato, Kensaku Kasuga, Noriko Isoo, Toshihiro Hayashi, Takeshi Ikeuchi, Yukiko Hori, Taisuke Tomita · 2023 · Neuroscience Research
  60. Modeling the Simultaneous Dynamics of Proteins in Blood Plasma and the Cerebrospinal Fluid in Human In Vivo
    Pierre Giroux, Jérôme Vialaret, Jana Kindermans, Audrey Gabelle, Luc Bauchet, Christophe Hirtz, Sylvain Lehmann, Jacques Colinge · 2024 · Journal of Proteome Research
  61. High Tau expression correlates with reduced invasion and prolonged survival in Ewing sarcoma
    Florencia Cidre‐Aranaz, Claudia Magrin, Malenka Zimmermann, Jing Li, Annalisa Baffa, Matteo Ciccaldo, Wolfgang Hartmann, Uta Dirksen, Martina Sola, Paolo Paganetti et al. · 2025 · Cell Death Discovery
  62. Current status and trends in the study of intestinal flora in cognitive disorders: a bibliometric and visual analysis
    Qi Zhang, Zhenmei Gao, Yunqing Deng, Xiangqing Xu, Wenyu Sun, Rui Liu, Tianao Zhang, Xilei Sun · 2025 · Frontiers in Microbiology
  63. Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline
    Ludivine Houzé, Marc Dhénain, Suzanne Lam, Fanny Petit, Stéphane Haı̈k, François Mouton‐Liger, Jacques Hugon, Julie Dam, Claire Paquet, Ralf Jockers et al. · 2025 · Alzheimer s Research & Therapy
  64. Clinical Validation of Plasma p‐217tau in Neurological Diseases
    Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari et al. · 2026 · Annals of Clinical and Translational Neurology
  65. Emerging directions in tauopathy research
    Luc Buée, Kristin R. Wildsmith, Suvarna Alladi, Taylor B. Bertucci, Delphine Boche, Kathryn R. Bowles, Adam L. Boxer, Jennifer Brummet, Sarah L. DeVos, Kristophe Diaz et al. · 2026 · Alzheimer s & Dementia
  66. Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease
    J Lee, Emily Olafson, Balazs Toth, Ellen Casavant, Stephen P. Schauer, Tobias Bittner, Matthew R. Meyer, Philip B. Verghese, Venky Venkatesh, Tim West et al. · 2026 · Alzheimer s & Dementia
  67. Detection of Alzheimer disease using deep learning
    Amira Ben Rabeh, Achraf Ben Miled, Aws Ismail Abu Eid · 2023 · Journal Of Advanced Zoology
  68. Novel Kinesin Family Member 1A Variants Linked to Atypical Parkinsonism Elicit Altered Neuronal Transactive Response DNA Binding Protein 43 kDa Interactions and Dendritic Atrophy
    Houman Homayoun, Michael R. DeChellis-Marks, Julia Kofler, Gabriella Fricklas, Amanda M. Gleixner, Fang-Cheng F. Yeh, David Lacomis, Charleen T. Chu, Christopher J. Donnelly · 2025 · American Journal Of Pathology
  69. A new step towards targeting tau
    Jean‐Christophe Corvol, Luc Buée · 2019 · The Lancet Neurology
  70. The dynamics behaviors of Chay neuron model under different parameters
    Kaijun Wu, Yu Chao, Dicong Wang · 2018 · Concurrency and Computation Practice and Experience
  71. Engineered Cerebral Organoids Recapitulate Adult Tau Expression and Disease-relevant Changes in Tau Splicing
    Christopher Edward James Lovejoy, Argyro Alatza, Charles Arber, Grant Galasso, Teisha Y. Bradshaw, An Verheyen, Tammaryn Lashley, Tamás Révész, John Hardy, Celeste M M. Karch et al. · 2020
  72. A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies
    Giavanna Paterno, Brach M. Bell, Kimberly-Marie M. Gorion, Stephan S. Quintin, Stefan Prokop, Benoit I. Giasson · 2025 · Scientific Reports
  73. Precision Diagnostics in Sports‐Related Traumatic Brain Injury: Pathophysiology, Biomarker Development and Emerging Technologies
    Daniel Nicol, Markand Dipankumar Patel, Debarati Bhowmik, Pola Goldberg Oppenheimer · 2025 · Advanced Sensor Research
  74. Post‐Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive Review
    Teesta Bhowmick, Ritojo Basu, Arup Kumar Mitra, Sk Asfaque Ali, Ajoy Kumer, Bikram Dhara · 2025 · Health Science Reports
  75. Tau pathology in epilepsy: emerging mechanisms and translational opportunities
    Arjune Sen, Xin You Tai, Aristea S. Galanopoulou, Maria Thom, Eleonora Aronica, Lucy E. Vivash, Martin Hardmeier, A. Amos, Stephan J. Rüegg, Matthias J. Koepp et al. · 2026 · Brain
  76. Multimorbidity and Associations with Cognition and Alzheimer's Disease Biomarkers
    Xiaqing Jiang, Sid E. O’Bryant, Robert A. Rissman, Leigh A Johnson, Meredith N. Braskie, Kristine S. Yaffe, The HABS-HD Study Team · 2026 · Annals of Neurology
  77. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer’s disease: randomised, controlled trial
    Zsófia Lovró, Anders Sandberg, Henrik Zetterberg, Stefan E. Pierrou, Riitta Parkkola, Niclas Sjögren, Mika Scheinin, Juha O. Rinne · 2026 · Alzheimer s Research & Therapy
  78. Dendritic translation and neuroproteasome-mediated degradation of endogenous tau revealed by STARFISH
    Kalin D. Konrad, Victoria Paradise, Lara Y. Demir, Chi Nguyen, Christopher D. Makinson, Zhao Ming, Kapil V. Ramachandran · 2026 · Nature Neuroscience
  79. MR Brain Screening using Optimization Techniques - A Survey
    D. Chitradevi, S. Prabha · 2021 · Current Medical Imaging Formerly Current Medical Imaging Reviews
  80. Prominent Perspective on Existing Biological Hallmarks of Alzheimer’s Disease
    Namrata Singh, Srishti Sharma, Kallol Kumar Ghosh, Bhanushree Gupta, Kamil Kuča · 2024 · Current Topics in Medicinal Chemistry
  81. Microfluidics in neural extracellular vesicles characterization for early Alzheimer's disease diagnosis
    Hossein Zare, Michelle Kasdorf, Amirala Bakhshian Nik · 2024 · Molecular and Cellular Neuroscience
  82. Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology
    Randall John Bateman, Tim West, Kevin E. Yarasheski, Bruce W. Patterson, Brendan P. Lucey, John R. Cirrito, Sylvain Lehmann, Christophe Hirtz, Audrey Gabelle, Timothy M. Miller et al. · 2019 · Handbook of behavioral neuroscience
  83. Detection of Tau-PET Positivity in Clinically Diagnosed Mild Cognitive Impairment with Multidimensional Features
    Bingyu Li, Alzheimer’s Disease Neuroimaging Initiative, Kening Shi, Chao Ren, Min Kong, Maowen Ba · 2023 · Journal of Alzheimer s Disease
  84. Neurotheranostics: The Next Frontier for Health Span
    Meryam Losee, John Peter Seibyl, Phillip H. Kuo · 2023 · Journal of Nuclear Medicine Technology
  85. Identifying shared diagnostic genes and mechanisms in vascular dementia and Alzheimer's disease via bioinformatics and machine learning
    Wanning Zheng, Dongdong Lin, Shunan Shi, Jiayi Ren, Jiong Wu, Ming Wang, Shu Wan · 2024 · Journal of Alzheimer s Disease Reports
  86. Biomarqueurs du liquide cérébrospinal
    Mélanie Leroy, Lucie Vaudran, Vincent Deramecourt, Florence Pasquier, Y. Chen, Susanna Schraen‐Maschke, Thibaud Lebouvier · 2021 · Pratique Neurologique - FMC
  87. Tau in Health and Neurodegenerative Diseases
    Dandan Chu, Fei Liu · 2021 · IntechOpen eBooks
  88. Tangles, not TANGO: targeting tau aggregates
    Andrew M. Stern, Reisa Anne Sperling · 2023 · Nature Aging
  89. Glymphatic system and aquaporin‑4 in epilepsy
    Dorota Nowicka · 2023 · Acta Neurobiologiae Experimentalis
  90. Ultrasensitive Assay Technologies
    Charles Shieh-Yueh Yang, Marwan Noel Sabbagh · 2026 · Springer eBooks
  91. Biomarker Candidates for Alzheimer’s Disease Unraveled through In Silico Differential Gene Expression Analysis
    Maria‐del‐Carmen Silva‐Lucero, Jared Rivera‐Osorio, Laura Gomez‐Virgilio, Gustavo López-Toledo, José Luna‐Muñoz, José Francisco Montiel-Sosa, Luis Oskar Soto-Rojas, Mar Pacheco‐Herrero, María del Carmen Cárdenas‐Aguayo · 2022 · Diagnostics
  92. A Method to Collect Cerebrospinal Fluid from Mouse Cisterna Magna to Determine Extracellular Tau Levels
    Kazuhisa Ishida, Kaoru Yamada · 2024 · Methods in molecular biology
  93. Method comparison and re-calibration of three top-used immunoassays and one LC-MS/MS assay for four core cerebrospinal fluid biomarkers of Alzheimer’s disease: an explorative study for harmonization
    Yutong Zou, Xiaoli Ma, Chenhui Mao, Shanshan Chu, Tianyi Wang, Wei Jin, Yifei Wang, Songlin Yu, Jing Gao, Ling Qiu · 2025 · Clinica Chimica Acta
  94. Synaptotoxic effects of extracellular tau are mediated by its microtubule-binding region
    Tomáš Ondrejčák, Neng‐Wei Hu, Emily Coode, Tom Campbell, Grant T. Corbett, Ivan Doykov, Kevin A. Mills, Dominic M. Walsh, Frederick J. Livesey, Michael J. Rowan et al. · 2025 · Acta Neuropathologica
  95. Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau
    Eliona Tsefou, Sumi Bez, Timothy J.Y. Birkle, Martha S. Foiani, Naoto Watamura, Mathieu Bourdenx, Daria Gavriouchkina, Emir Turkes, Samuel Crawford, Rachel Coneys et al. · 2026 · Science Advances
  96. The application of directly induced neurons into neurodegenerative disease modeling
    Keita Matsumoto, Sumihiro Maeda · 2025 · Neuroscience Research
  97. post translational modifications in the brain are critical contributors to Alzheimer's disease neuropathology and cognitive decline
    Julia B. Libby, Emily R. Mahoney, Ben Drucker, Philip L. De Jager, Vilas Menon, Shahram Oveisgharan, Julie A. Schneider, Lisa Laverne Barnes, David A. Bennett, Vladislav A. Petyuk et al. · 2025 · Alzheimer s & Dementia
  98. Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial
    Günter U. Höglinger, Wim Vandenberghe, Dirk Woitalla, Jean‐Christophe Corvol, Hans Lieve G. Van Tricht, Colin Ewen, Bart Van Den Steen, Irene Rebollo Mesa, Massimiliano Germani, Elodie Garric et al. · 2026 · BMJ Neurology Open
  99. Research progress on biomarkers of traumatic brain injury
    Xuting Shen, Si Cheng, Shuyi Chen, M Wang, Tangying Li, Weicheng Xu, Yifan Zhang, Ping Yuan, Le Shi · 2026 · Animal Models and Experimental Medicine
  100. Plasma p-tau217 measured by the Elecsys automated immunoassay: Prospective validation in a heterogeneous memory clinic cohort
    E. Franco-Macías, J. Noval-Padillo, Rocío Hervás-Navidad, B. Espejo-Martínez, Cristina Serrano-Gutiérrez, S. Rodrigo-Herrero, C. Méndez-Barrio, Gonzalo Mendoza-Vázquez, I. Carrera-Muñoz, B. Marín-Romero et al. · 2026 · Journal of Alzheimer's Disease